RxDoctor Payments Data

John Pacanowski, MD

Vascular Surgery · Tucson, AZNPI 1083606669

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Philips North America LLC at 28.3% of the total. Reporting peaked in 2019 at $43,772 and has fallen 96.1% since, to $1,721 in 2025. Among vascular surgery clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,036in general payments, 2019–2025

Across 211 payments — averaging $403.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$24K
  • Angiodynamics, Inc.$19K
  • Genentech USA, Inc.$11K
  • Bard Peripheral Vascular, Inc.$10K
  • Endologix LLC$9K
  • Abbott$5K
  • plus $7K from 18 others

What the payments were for

  • Consulting fees$37,07844%
  • Speaking & faculty fees$30,40036%
  • Travel & lodging$5,2876%
  • Food & beverage$10,16812%
  • Education$2,0372%
  • Other$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,036 in reported general payments places this provider in the 90th percentile of 105 vascular surgery providers in Arizona.

See all vascular surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$5,219
Medicare patients
24
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$9,273
ClopidogrelClopidogrel Bisulfate20$356

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →